Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 12, 2024
Daily News
December 12, 2024
- Daiichi Kicks Off PIII Quizartinib Study for FLT3-ITD Negative AML
December 12, 2024
- EFPIA Japan Issues Joint Statement for Resolving Drug Lags/Losses
December 12, 2024
- Chuikyo Doctor Rep Positive on Industry’s Behavioral Changes after 2024 Reform
December 12, 2024
- JGA to Compile Interim Report on Generic Industry Revamp in May
December 12, 2024
- Hearing Leaves Chuikyo Mixed on Off-Year Scheme, Political Decision Ever More Likely
December 12, 2024
- Kyowa Kirin to Globalize Research Organization after Orchard Buy
December 12, 2024
- Santen’s Glaucoma Drug Accepted for Review in Korea, Vietnam
December 12, 2024
- Eisai’s Gout Drug Urece Wins Nod in China
December 12, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…